Young Adults with Acute Lymphoblastic Leukemia
common.study.values.description
“Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia”
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute lymphoblastic leukemia.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Allopurinol
Given PO
Drug - Cytarabine
Given IT, IV, SC
Drug - Daunorubicin Hydrochloride
Given IV
Drug - Vincristine Sulfate
Given IV
Drug - Dexamethasone
Given PO or IV
Drug - Pegylated L-Asparaginase
Given IV
Drug - Methotrexate
Given IT, IV, PO
Procedure - Bone Marrow Aspiration and Biopsy
Undergo bone marrow aspiration and biopsy
Drug - Cyclophosphamide
Given IV
Drug - Mercaptopurine
Given PO
Biological - Rituximab
Given IV
Drug - Doxorubicin
Given IV
Drug - Thioguanine
Given PO
Biological - Inotuzumab Ozogamicin
Given IV
Laboratory Biomarker Analysis
Correlative studies
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
common.study.values.clinical-trial-id
NCT03150693
participant.views.study.view.id
xe7qjb
